PHARMACEUTICAL COMPANY AstraZeneca will pay $1.1bn to resolve an ongoing transfer pricing dispute over its US business.
The UK-Swedish based firm will pay the $1.1bn net costs to US tax authorities to cover transfer pricing arrangements over a 13-year period from 2002 to the end of 2014, it announced today. It had already announced in February that it will pay £505m to settle a dispute with HM Revenue & Customs.
“AstraZeneca had provided in its accounts for the outcome of these issues, at the heart of which are complex transfer pricing considerations that have taken many years to resolve,” the group said.
It also said that the group’s effective tax rate for 2011 is expected to be approximately six percentage points lower than the previous guidance of 27%, at around 21%.
Making Tax Digital will impose significant additional tax compliance costs on small businesses for little or no medium term benefit, tax and small business experts told MPs
MHA MacIntyre Hudson has partnered with cloud accounting software provider Xero ahead of the government’s requirement for digital records
The drive towards a fully digital tax regime is an admirable one, but mandation is simply wrong, according to one of the UK's most senior tax technology practitioners - Paul Aplin
Does Darwin's theory apply to taxation? Colin ponders...